What is NantOmics?
NantOmics operates at the intersection of advanced biotechnology and clinical decision support, positioning itself as a leader in molecular testing. The company specializes in the detection of complex genomic and proteomic alterations, providing a comprehensive panomic view of tumor biology. By integrating DNA sequencing, RNA sequencing, and quantitative proteomics, NantOmics delivers actionable intelligence that empowers healthcare providers to tailor treatment protocols to the specific molecular profile of an individual patient.
This integrated approach is essential for the advancement of personalized medicine, as it moves beyond traditional diagnostic methods to identify targeted therapeutic interventions. Through its proprietary analytical platform, the company bridges the gap between raw biological data and clinical application, ultimately aiming to improve patient outcomes in oncology through data-driven precision.
How much funding has NantOmics raised?
NantOmics has raised a total of $260.9M across 4 funding rounds:
Multiple Rounds
$260.9M
Private Equity (2015): $10M, investors not publicly disclosed
Private Equity (2015): $100M, investors not publicly disclosed
Private Equity (2015): $150M, investors not publicly disclosed
Private Equity (2015): $906K, investors not publicly disclosed
Key Investors in NantOmics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for NantOmics?
With the recent influx of capital, NantOmics is poised to transition into a more aggressive phase of enterprise-level scaling. The strategic focus will likely center on enhancing the throughput of its sequencing and proteomic pipelines, ensuring that its decision support tools remain at the forefront of clinical utility. As the demand for personalized cancer care continues to rise, the company is strategically positioned to leverage its panomic data assets to forge deeper partnerships with pharmaceutical developers and clinical research institutions.
Future initiatives will likely prioritize the expansion of its diagnostic footprint, potentially integrating artificial intelligence to further streamline the interpretation of complex molecular datasets. By maintaining its focus on high-fidelity molecular profiling, NantOmics is set to solidify its influence in the precision medicine ecosystem, driving innovation that directly impacts the efficacy of targeted cancer therapies.
